• Publications
  • Influence
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.
BACKGROUND Patients infected with hepatitis C virus (HCV) genotype 2 or 3 have sustained virologic response rates of approximately 80% after receiving treatment with peginterferon and ribavirin forExpand
  • 597
  • 32
  • PDF
Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector
Interferon (IFN) α inhibits hepatitis C virus (HCV) replication both clinically and in vitro; however, the complete spectrum of interferon‐stimulated genes (ISGs) expressed in the HCV‐infected liverExpand
  • 225
  • 10
Transferrin index: an alternative method for calculating the iron saturation of transferrin.
We surveyed 140 clinical chemistry laboratories in Australia to establish which laboratory methods they used to determine serum iron status: 125 measured serum iron (Fe), 85 measured transferrinExpand
  • 67
  • 4
Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
BACKGROUND & AIMS Twenty-four weeks of treatment with peginterferon and ribavirin for chronic hepatitis C virus (HCV) genotype 2 or 3 infection produces a sustained virologic response (SVR) inExpand
  • 59
  • 4
Donor mannose-binding lectin deficiency increases the likelihood of clinically significant infection after liver transplantation.
BACKGROUND Mannose-binding lectin (MBL) is an important mediator of innate immunity and is synthesized primarily by the liver. Low MBL levels are common, are due primarily to polymorphisms in theExpand
  • 65
  • 3
  • PDF
Differential Expression of the CXCR3 Ligands in Chronic Hepatitis C Virus (HCV) Infection and Their Modulation by HCV In Vitro
ABSTRACT To investigate chemokine expression networks in chronic hepatitis C virus (HCV) infection, we used microarray analysis to determine chemokine expression in human infection and in chimpanzeesExpand
  • 68
  • 3
Expression of the CXCR3 ligand I‐TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation
The factors that regulate lymphocyte traffic in chronic hepatitis C (CHC) are not completely defined. Interferon (IFN)‐inducible T cell α chemoattractant (I‐TAC) is a relatively new member of theExpand
  • 116
  • 2
Combination low‐dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B
Although antiviral prophylaxis with lamivudine monotherapy appears to reduce post–liver transplantation recurrence of hepatitis B virus (HBV) infection, breakthrough infections occur in at least 20%Expand
  • 239
  • 1
High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C
Background and Aim:  Prisoners have a high prevalence of injection drug use (IDU) and chronic hepatitis C (CHC) infection. Treatment of CHC in these patients is effective; however, their long‐termExpand
  • 48
  • 1
Factors associated with severity of hepatic fibrosis in people with chronic hepatitis C infection
Objective: To determine factors associated with hepatic fibrosis development in people with chronic hepatitis C virus (HCV) infection.
  • 29
  • 1
  • PDF